Roswell Park forms for-profit biotechnology company

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ROSWELL PARK CANCER INSTITUTE announced the formation of Global Biotechnology & Cancer Therapeutics, a for-profit company that will support biotech and life-sciences startups. “GBCT will allow outside biotechnology companies to partner with a scientifically respected entity that will provide infrastructure for drug development and investment — everything from clinical trials to anticancer agents and vaccines,...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login